Abstract
Objective
To characterize continuous video electroencephalogram (VEEG) findings of hospitalized COVID-19 patients.
Methods
We performed a retrospective chart review of patients admitted at three New York City hospitals who underwent VEEG at the peak of the COVID-19 pandemic. Demographics, comorbidities, neuroimaging, VEEG indications and findings, treatment, and outcomes were collected.
Results
Of 93 patients monitored, 77% had severe COVID-19 and 40% died. Acute ischemic or hemorrhagic stroke was present in 26% and 15%, respectively. Most common VEEG indications were encephalopathy/coma (60%) and seizure-like movements (38%). Most common VEEG findings were generalized slowing (97%), generalized attenuation (31%), generalized periodic discharges (17%) and generalized sharp waves (15%). Epileptiform abnormalities were present in 43% and seizures in 8% of patients, all of whom had seizure risk factors. Factors associated with an epileptiform VEEG included increasing age (OR 1.07, p = 0.001) and hepatic/renal failure (OR 2.99, p = 0.03).
Conclusions
Most COVID-19 patients who underwent VEEG monitoring had severe COVID-19 and over one-third had acute cerebral injury (e.g., stroke, anoxia). Seizures were uncommon. VEEG findings were nonspecific.
Significance
VEEG findings in this cohort of hospitalized COVID-19 patients were those often seen in critical illness. Seizures were uncommon and occurred in the setting of common seizure risk factors.
【저자키워드】 COVID-19, NeuroCOVID, EEG, Electroencephalography, Seizures, 【초록키워드】 Treatment, Risk factors, severe COVID-19, stroke, COVID-19 pandemic, hospital, Comorbidities, outcome, discharge, New York City, Cohort, Patient, Critical, patients, hospitalized COVID-19 patient, retrospective, Injury, Seizure, COVID-19 patient, Hemorrhagic Stroke, Factor, hospitalized COVID-19 patients, indication, increasing age, abnormality, MOST, objective, electroencephalogram, Result, performed, collected, occurred, died, epileptiform, nonspecific, Significance, 【제목키워드】 patients with COVID-19,